Inovio Pharmaceuticals (INO) 10-Q 12 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 04, 2013
Document and Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Entity Registrant Name	'INOVIO PHARMACEUTICALS, INC.	'
Entity Central Index Key	'0001055726	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	208,376,469

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013		Dec. 31, 2012
Current assets:	'		'
Cash and cash equivalents	$33,067,421		$5,646,021
Short-term investments	13,104,863		8,034,001
Accounts receivable	10,574,199		830,433
Accounts receivable from affiliated entity	0		36,234
Prepaid expenses and other current assets	471,867		471,328
Prepaid expenses and other current assets from affiliated entity	573,017		887,167
Deferred tax asset	62,728		62,728
Total current assets	57,854,095		15,967,912
Restricted cash	100,674		100,410
Fixed assets, net	2,290,566		363,021
Investment in affiliated entity	11,084,123		10,703,332
Intangible assets, net	6,156,635		7,489,315
Goodwill	10,113,371	[1]	10,113,371	[1]
Common stock warrants	244,900		267,200
Other assets	171,000		134,193
Total assets	88,015,364		45,138,754
Current liabilities:	'		'
Accounts payable and accrued expenses	4,020,494		3,181,574
Accounts payable and accrued expenses due to affiliated entity	494,460		187,275
Accrued clinical trial expenses	1,359,071		1,405,896
Common stock warrants	14,095,818		2,859,899
Deferred revenue	66,998		353,391
Deferred revenue from affiliated entity	401,041		388,542
Total current liabilities	20,437,882		8,376,577
Deferred revenue, net of current portion	1,724,547		88,609
Deferred revenue from affiliated entity, net of current portion	1,305,444		1,586,694
Deferred rent	2,166,849		65,076
Deferred tax liabilities	164,393		164,393
Total liabilities	25,799,115		10,281,349
Inovio Pharmaceuticals, Inc. stockholders’ equity:	'		'
Common stock	207,620		144,313
Additional paid-in capital	341,979,766		263,897,116
Accumulated deficit	-280,334,247		-229,760,129
Accumulated other comprehensive (loss) income	-98,022		73,362
Total Inovio Pharmaceuticals, Inc. stockholders’ equity	61,755,117		34,354,662
Non-controlling interest	461,132		502,743
Total stockholders' equity	62,216,249		34,857,405
Total liabilities and stockholders’ equity	$88,015,364		$45,138,754
[1]	Goodwill was recorded from the Inovio AS acquisition in January 2005 and from the acquisition of VGX in June 2009 for $3.9 million and $6.2 million, respectively.

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues:	'	'	'	'
License fee and milestone revenue	$8,388,760	$22,495	$8,417,330	$68,240
License fee and milestone revenue from affiliated entity	106,250	106,250	318,750	318,750
Revenue under collaborative research and development arrangements with affiliated entity	'	116,234	0	116,234
Grants and miscellaneous revenue	991,835	609,717	2,991,600	2,480,675
Total revenues	9,486,845	854,696	11,727,680	2,983,899
Operating expenses:	'	'	'	'
Research and development	5,438,405	4,972,319	14,964,599	13,541,984
General and administrative	3,282,796	2,674,362	9,303,535	7,859,359
Gain on sale of assets	0	-500,000	-1,000,000	-1,151,000
Total operating expenses	8,721,201	7,146,681	23,268,134	20,250,343
Income (Loss) from operations	765,644	-6,291,985	-11,540,454	-17,266,444
Other income (expense):	'	'	'	'
Interest and other income, net	46,787	37,013	123,638	109,593
Change in fair value of common stock warrants	-34,952,210	-1,113,638	-39,579,704	-1,067,029
Gain (Loss) on investment in affiliated entity	3,248,926	736,121	380,791	-817,796
Net loss	-30,890,853	-6,632,489	-50,615,729	-19,041,676
Net loss attributable to non-controlling interest	13,443	10,413	41,611	31,472
Net loss attributable to Inovio Pharmaceuticals, Inc.	($30,877,410)	($6,622,076)	($50,574,118)	($19,010,204)
Loss per common share—basic and diluted:	'	'	'	'
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders (in USD per share)	($0.16)	($0.05)	($0.29)	($0.14)
Weighted average number of common shares outstanding—basic and diluted	191,956,155	135,389,308	176,183,075	135,108,699

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net loss	($30,890,853)	($6,632,489)	($50,615,729)	($19,041,676)
Other comprehensive income (loss):	'	'	'	'
Foreign currency translation adjustments	1,331	684	-344	697
Unrealized (loss) gain on short-term investments	-2,917	27,904	-171,040	57,012
Comprehensive loss	-30,892,439	-6,603,901	-50,787,113	-18,983,967
Comprehensive loss attributable to non-controlling interest	13,443	10,413	41,611	31,472
Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.	($30,878,996)	($6,593,488)	($50,745,502)	($18,952,495)

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:	'	'
Net loss	($50,615,729)	($19,041,676)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation	124,552	124,123
Amortization of intangible assets	1,332,680	1,370,744
Change in value of common stock warrants	39,579,704	1,067,029
Stock-based compensation	1,338,427	1,176,874
Interest income accrued on short-term investments	-507	-1,148
Deferred rent	300,273	-10,852
(Gain) Loss on investment in affiliated entity	-380,791	817,796
Transaction costs associated with issuance of warrants	315,970	0
Gain on sale of intangible assets	-1,000,000	-1,151,000
Changes in operating assets and liabilities:	'	'
Accounts receivable	-9,743,766	-13,538
Accounts receivable from affiliated entity	36,234	-95,914
Prepaid expenses and other current assets	-64,139	258,328
Prepaid expenses and other current assets from affiliated entity	314,150	-245,440
Restricted cash	-264	-264
Other assets	26,793	-14,794
Accounts payable and accrued expenses	792,095	-860,232
Accounts payable and accrued expenses due to affiliated entity	307,185	89,757
Deferred revenue	1,349,545	14,465
Deferred revenue from affiliated entity	-268,751	-268,750
Net cash used in operating activities	-16,256,339	-16,784,492
Cash flows from investing activities:	'	'
Purchases of investments	-5,691,902	-7,642,157
Maturities of investments	450,507	10,008,771
Purchases of capital assets	-250,597	-219,865
Proceeds from sale of intangible assets	1,000,000	650,000
Net cash (used in) provided by investing activities	-4,491,992	2,796,749
Cash flows from financing activities:	'	'
Proceeds from issuance of common stock and warrants, net of issuance costs	29,077,495	1,225,588
Proceeds from stock option and warrant exercises	19,092,580	0
Net cash provided by financing activities	48,170,075	1,225,588
Effect of exchange rate changes on cash and cash equivalents	-344	697
Increase (Decrease) in cash and cash equivalents	27,421,400	-12,761,458
Cash and cash equivalents, beginning of period	5,646,021	17,350,116
Cash and cash equivalents, end of period	$33,067,421	$4,588,658

Description_of_Business

Description of Business	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Description of Business	'
	Description of Business
	Inovio Pharmaceuticals, Inc. (the “Company” or “Inovio”) is engaged in the discovery and development of a new generation of vaccines and immune therapies, called synthetic vaccines, focused on cancers and infectious diseases. The Company's DNA-based SynCon® technology is designed to provide universal protection against known as well as new unmatched strains of pathogens such as influenza and also generate strong T-cell responses to fight cancers and infectious diseases. The Company's preclinical development and clinical programs include cervical dysplasia/cancer (therapeutic), influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus, hepatitis B virus, HIV, and malaria vaccines. The Company's partners and collaborators include Roche, University of Pennsylvania, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, Program for Appropriate Technology in Health/Malaria Vaccine Initiative (“PATH” or “MVI”), National Institute of Allergy and Infectious Diseases (“NIAID”), Merck, University of Southampton, United States Military HIV Research Program (“USMHRP”), U.S. Army Medical Research Institute of Infectious Diseases (“USAMRIID”), HIV Vaccines Trial Network (“HVTN”) and Department of Homeland Security (“DHS”).

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of September 30, 2013, condensed consolidated statements of operations for the three and nine months ended September 30, 2013 and 2012, condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2013 and 2012 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2013 and 2012, are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented. The results of operations for the three and nine months ended September 30, 2013 shown herein are not necessarily indicative of the results that may be expected for the year ending December 31, 2013, or for any other period. These financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2012, included in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on March 18, 2013. The balance sheet at December 31, 2012 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The Company has evaluated subsequent events after the balance sheet date of September 30, 2013 through the date it filed these unaudited condensed consolidated financial statements with the SEC.
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	The Company incurred a net loss of $30.9 million and $50.6 million, respectively, for the three and nine months ended September 30, 2013. The Company had working capital of $37.4 million and an accumulated deficit of $280.3 million as of September 30, 2013. The Company’s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These unaudited interim condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should the Company be unable to continue in business. The Company's unaudited interim condensed consolidated financial statements as of and for the period ended September 30, 2013 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future.

Impact_of_Recently_Issued_Acco

Impact of Recently Issued Accounting Standards	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Impact of Recently Issued Accounting Standards	'
	Impact of Recently Issued Accounting Standards
	The recent pronouncements below may have a significant effect on the Company's financial statements. Recent pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.
	Accounting Standards Update (“ASU”), No. 2013-02-In February 2013, the Financial Accounting Standards Board (“FASB”) issued an ASU which amended the disclosure requirements regarding the reporting of amounts reclassified out of accumulated other comprehensive income. The amendment does not change the current requirement for reporting net income or other comprehensive income, but requires additional disclosures about significant amounts reclassified out of accumulated other comprehensive income including the effect of the reclassification on the related net income line items. The Company has adopted ASU 2013-02 prospectively effective January 1, 2013 and the adoption is not expected to have a significant impact on its financial statements as the requirements are disclosure only in nature.

Principles_of_Consolidation

Principles of Consolidation	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation
	These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiaries. In conjunction with the acquisition in June 2009 of VGX Pharmaceuticals (the “Merger”), the Company acquired an 88% interest in VGX Animal Health and certain shares in VGX International, Inc. (“VGX Int'l”) (a publicly-traded company in South Korea). The Company consolidates Genetronics, Inc., VGX Pharmaceuticals and its subsidiary VGX Animal Health and records a non-controlling interest for the 9% of VGX Animal Health it does not own as of September 30, 2013 and December 31, 2012. The Company's investment in VGX Int'l, which is recorded as investment in affiliated entity within the condensed consolidated balance sheets is accounted for at fair value on a recurring basis, with changes in fair value recorded on the condensed consolidated statements of operations within gain (loss) on investment in affiliated entity. All intercompany accounts and transactions have been eliminated upon consolidation.
	Variable Interest Entities
	In June 2009, the FASB issued authoritative guidance that requires companies to perform a qualitative analysis to determine whether a variable interest in another entity represents a controlling financial interest in a variable interest entity. A controlling financial interest in a variable interest entity is characterized by having both the power to direct the most significant activities of the entity and the obligation to absorb losses or the right to receive benefits of the entity. This guidance also requires on-going reassessments of variable interests based on changes in facts and circumstances. This guidance became effective for fiscal years beginning after November 15, 2009. The Company adopted the provisions of the guidance in the first quarter of 2010 and determined that none of the entities with which the Company currently conducts business and collaborations are variable interest entities, except VGXI (a wholly-owned subsidiary of VGX Int'l). The Company determined that they are not the primary beneficiary and therefore are not required to consolidate VGXI. The Company continues to assess its variable interests and has determined that no significant changes have occurred as of September 30, 2013.

Investments

Investments	9 Months Ended
	Sep. 30, 2013
Investments, Debt and Equity Securities [Abstract]	'
Investments	'
	Investments
	Investments consist of mutual funds at September 30, 2013 and of certificates of deposit, mutual funds, and municipal bonds at December 31, 2012. The Company classifies all investments as available-for-sale, as the sale of such investments may be required prior to maturity to implement management strategies. These investments are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) until realized. A decline in the market value of any investment below cost that is determined to be other-than-temporary will result in a revaluation of its carrying amount to fair value. The impairment is charged to earnings and a new cost basis for the investment is established. No such impairment charges were recorded during the three and nine months ended September 30, 2013.
	The following is a summary of investments as of September 30, 2013 and December 31, 2012:
			As of September 30, 2013
		Contractual	Cost		Gross Unrealized		Gross Unrealized			Fair Market Value
		Maturity (in years)			Gains		Losses
	Mutual funds	Less than 1	$	13,191,964	$	—	$	(87,101	)	$	13,104,863
	Total investments		$	13,191,964	$	—	$	(87,101	)	$	13,104,863
			As of December 31, 2012
		Contractual	Cost		Gross Unrealized		Gross Unrealized			Fair Market Value
		Maturity (in years)			Gains		Losses
	Mutual funds	Less than 1	$	7,500,063	$	83,868	$	—		$	7,583,931
	Certificates of deposit	Less than 1	250,000		—		—			250,000
	Municipal bonds	Less than 1	201,470		—		(1,400		)	200,070
	Total investments		$	7,951,533	$	83,868	$	(1,400	)	$	8,034,001

Marketable_Securities_and_Fair

Marketable Securities and Fair Value Measurements	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Marketable Securities and Fair Value Measurements	'
	Marketable Securities and Fair Value Measurements
	The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
	The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2013:
		Fair Value Measurements at
		September 30, 2013
		Total			Using Quoted Prices		Using Significant		Using Significant
					in Active Markets		Other Unobservable		Unobservable
					for Identical Assets		Inputs		Inputs
					(Level 1)		(Level 2)		(Level 3)
	Assets:
	Money market funds	$	18,338,897		$	18,338,897	$	—	$	—
	Mutual funds	13,104,863			—		13,104,863		—
	Investment in affiliated entity	11,084,123			11,084,123		—		—
	Common stock warrants	244,900			—		—		244,900
	Total Assets	$	42,772,783		$	29,423,020	$	13,104,863	$	244,900
	Liabilities:
	Common stock warrants	$	14,095,818		$	—	$	—	$	14,095,818
	Total Liabilities	$	14,095,818		$	—	$	—	$	14,095,818
	The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2012:
		Fair Value Measurements at
		December 31, 2012
		Total			Using Quoted Prices		Using Significant		Using Significant
					in Active Markets		Other Unobservable		Unobservable
					for Identical Assets		Inputs		Inputs
					(Level 1)		(Level 2)		(Level 3)
	Assets:
	Money market funds	$	1,686,406		$	1,686,406	$	—	$	—
	Mutual funds	7,583,931			—		7,583,931		—
	Certificates of deposit	250,000			—		250,000		—
	Municipal bonds	200,070			—		200,070		—
	Investment in affiliated entity	10,703,332			10,703,332		—		—
	Common stock warrants	267,200			—		—		267,200
	Total Assets	$	20,690,939		$	12,389,738	$	8,034,001	$	267,200
	Liabilities:
	Common stock warrants	$	2,859,899		$	—	$	—	$	2,859,899
	Total Liabilities	$	2,859,899		$	—	$	—	$	2,859,899
	Level 1 assets include money market funds held by the Company that are valued at quoted market prices, as well as the Company’s investment in VGX Int’l, for which the fair value is based on the market value of 8,220,775 common shares on September 30, 2013 and December 31, 2012, listed on the Korean Stock Exchange. The Company accounts for its investment at fair value on a recurring basis.
	Level 2 assets at September 30, 2013 include mutual funds held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. We obtain the fair value of our Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. Our professional pricing service gathers quoted market prices and observable inputs for all of mutual funds from a variety of industry data providers. The valuation techniques used to measure the fair value of our Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. We validate the quoted market prices provided by our primary pricing service by comparing their assessment of the fair values of our investment portfolio balance against the fair values of our investment portfolio balance obtained from an independent source, which may include our investment managers.
	Level 3 assets at September 30, 2013 include two warrants received by the Company to purchase shares of common stock of OncoSec Medical Incorporated (“OncoSec”), in connection with the first and second amendments to the Asset Purchase Agreement between the Company and OncoSec signed in September 2011 and March 2012, respectively. The first warrant to purchase 1,000,000 shares of common stock of OncoSec has a contractual life of five years with an exercise price of $1.20 per share. The second warrant to purchase 3,000,000 shares of common stock of OncoSec has a contractual life of five years with an exercise price of $1.00 per share.
	As of September 30, 2013 the Company recorded a long-term asset of approximately $245,000 associated with the warrants received to purchase common stock of OncoSec. The Company valued the warrants received in March 2012 as of the issuance date using the Black Scholes pricing model and recorded a $501,000 gain on sale of assets within the condensed consolidated statement of operations. Inputs used in the pricing model include estimates of OncoSec stock price volatility, expected warrant life and risk-free interest rate. The Company develops its estimates based on publicly available historical data and knowledge of OncoSec. The Company reassesses the fair value of the warrants at each reporting date. The assumptions used to estimate the fair values of the OncoSec common stock warrants at September 30, 2013 are presented below:
	Risk-free interest rate	0.63%
	Expected volatility	85%
	Expected life in years	3-3.5
	Dividend yield	—
	As a result of these calculations, the Company recorded a decrease in fair value of the two warrants of $21,000 and $22,000 for the three and nine months ended September 30, 2013, respectively, and an increase (decrease) in fair value of the two warrants of $11,000 and $(80,000) for the three and nine months ended September 30, 2012, respectively. The change in fair value is reflected in the Company's condensed consolidated statement of operations as a component of change in fair value of common stock warrants.
	The following table presents a summary of changes in fair value of the Company’s total Level 3 financial assets for the nine months ended September 30, 2013:
	Balance at January 1, 2013	$	267,200
	Decrease in fair value included in change in fair value of common stock warrants	(22,300		)
	Balance at September 30, 2013	$	244,900
	Level 3 liabilities held as of September 30, 2013 consist of common stock warrant liabilities associated with warrants to purchase the Company's common stock issued in July 2009, January 2011 and March 2013. Level 3 liabilities held as of December 31, 2012 consist of common stock warrant liabilities associated with warrants to purchase the Company's common stock issued in July 2009, January 2011, December 2011 and March 2013. During the three and nine months ended September 30, 2013, warrants to purchase 20,584,997 shares of common stock were exercised.
	As of September 30, 2013 the Company recorded a $14.1 million common stock warrant liability. The Company reassesses the fair value and the related inputs to determine the fair value of the common stock warrants at each reporting date utilizing a Black-Scholes pricing model. Inputs used in the pricing models include estimates of stock price volatility, expected warrant life and risk-free interest rate. The Company develops its estimates based on historical data. The range of assumptions used to estimate the fair values of common stock warrants at September 30, 2013 are presented below:
	Risk-free interest rate	0.13%-1.52%
	Expected volatility	88%-119%
	Expected life in years	0.75-4.96
	Dividend yield	—
	Changes in these assumptions as well as in the Company's stock price on the valuation date can have a significant impact on the fair value of the common stock warrant liability. As a result of these calculations, the Company recorded an increase in fair value of $34.9 million and $39.6 million for the three and nine months ended September 30, 2013, respectively, and an increase in fair value of $1.1 million and $987,000 for the three and nine months ended September 30, 2012, respectively. The significant change in fair value was primarily due to the increase in the Company's stock price during the period. The change in fair value is reflected in the Company's condensed consolidated statement of operations as a component of change in fair value of common stock warrants. Warrants that were exercised during the period were revalued on the day prior to exercise and then reclassified into stockholders' equity upon exercise.
	The following table presents the changes in fair value of the Company’s total Level 3 financial liabilities for the nine months ended September 30, 2013:
	Balance at January 1, 2013	$	2,859,899
	Record fair value of warrants issued in March 2013 financing	5,968,244
	Increase in fair value included in change in fair value of common stock warrants	39,557,404
	Change in classification from liability to stockholders' equity due to warrant exercises	(34,289,729		)
	Balance at September 30, 2013	$	14,095,818

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets	'
	Goodwill and Intangible Assets
	The following sets forth the goodwill and intangible assets by major asset class:
			September 30, 2013							December 31, 2012
		Useful	Gross		Accumulated			Net Book		Gross		Accumulated			Net Book
		Life			Amortization			Value				Amortization			Value
		(Yrs)
	Non-Amortizing:
	Goodwill(a)		$	10,113,371	$	—		$	10,113,371	$	10,113,371	$	—		$	10,113,371
	Amortizing:
	Patents	8 – 17	5,802,528		(5,064,115		)	738,413		5,802,528		(4,852,673		)	949,855
	Licenses	8 – 17	1,323,761		(1,068,431		)	255,330		1,323,761		(1,046,870		)	276,891
	CELLECTRA®(b)	5 – 11	8,106,270		(5,241,398		)	2,864,872		8,106,270		(4,334,234		)	3,772,036
	GHRH(b)	11	335,314		(137,294		)	198,020		335,314		(113,531		)	221,783
	Other(c)	18	4,050,000		(1,950,000		)	2,100,000		4,050,000		(1,781,250		)	2,268,750
	Total intangible assets		19,617,873		(13,461,238		)	6,156,635		19,617,873		(12,128,558		)	7,489,315
	Total goodwill and intangible assets		$	29,731,244	$	(13,461,238	)	$	16,270,006	$	29,731,244	$	(12,128,558	)	$	17,602,686
	(a)	Goodwill was recorded from the Inovio AS acquisition in January 2005 and from the acquisition of VGX in June 2009 for $3.9 million and $6.2 million, respectively.
	(b)	CELLECTRA® and GHRH are developed technologies which were recorded from the acquisition of VGX.
	(c)	Other intangible assets represent the fair value of acquired contracts and intellectual property from the Inovio AS acquisition.
	Aggregate amortization expense on intangible assets for the three and nine months ended September 30, 2013 was $440,000 and $1.3 million, respectively. Aggregate amortization expense on intangible assets for the three and nine months ended September 30, 2012 was $453,000 and $1.4 million, respectively. Estimated aggregate amortization expense for each of the five succeeding fiscal years is $438,000 for the remainder of fiscal year 2013, $943,000 for 2014, $870,000 for 2015, $816,000 for 2016, $775,000 for 2017 and $773,000 for 2018.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity	'
	Stockholders’ Equity
	The following is a summary of the Company's authorized and issued common and preferred stock as of September 30, 2013 and December 31, 2012:
							Outstanding as of
		Authorized			Issued		September 30,		December 31,
							2013		2012
	Common Stock, par $0.001	600,000,000			207,620,037		207,620,037		144,313,005
	Series A Preferred Stock, par $0.001	1,000			817		—		—
	Series B Preferred Stock, par $0.001	1,000			750		—		—
	Series C Preferred Stock, par $0.001	1,091			1,091		26		26
	Series D Preferred Stock, par $0.001	1,966,292			1,966,292		—		—
	Common Stock
	In May 2013, the Company filed a Certificate of Amendment to the Certificate of Incorporation with the Delaware Secretary of State. The Certificate of Amendment increased the number of shares of common stock the Company has the authority to issue from 300,000,000 shares to 600,000,000 shares.
	In March 2013, the Company completed an underwritten offering of 27,377,266 shares of common stock and warrants to purchase an aggregate of up to 13,688,633 shares of common stock. The shares and warrants were sold in units at a price of $0.55 per unit, with each unit consisting of one share of common stock and a warrant to purchase 0.50 share of common stock at an exercise price of $0.7936 per share. The warrants have a term of five and one-half years. The net proceeds, after deducting the underwriters' discounts and other offering expenses, were approximately $14.0 million. The Company valued the registered warrants issued in connection with the March 2013 financing as of the issuance date using the Black Scholes pricing model and recorded a current liability on the condensed consolidated balance sheet of $6.0 million. The warrants were subsequently revalued and the Company recorded the increase in fair value of $19.6 million and $22.7 million to change in fair value of common stock warrants on the condensed consolidated statement of operations for the three and nine months ended September 30, 2013, respectively. As of September 30, 2013, 10,290,908 of these warrants had been exercised. Transaction costs associated with the issuance of the warrants were allocated by using the relative fair value approach. These transaction costs of $316,000 were immediately expensed and included as part of general and administrative expense in the Company's condensed consolidated statement of operations for the nine months ended September 30, 2013.
	In June 2012, the Company entered into an "at-the-market" (ATM) sales agreement (the “Sales Agreement”) with an outside placement agent (the “Placement Agent”) to sell shares of its common stock with aggregate gross proceeds of up to $25.0 million from time to time, through an ATM equity offering program under which the Placement Agent will act as sales agent. Under the Sales Agreement, the Company will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. The Sales Agreement provides that the Placement Agent will be entitled to compensation for its services in an amount equal to 3.0% of the gross proceeds from the sales of shares sold through the Placement Agent under the Sales Agreement. The Company has no obligation to sell any shares under the Sales Agreement, and may at any time suspend solicitation and offers under the Sales Agreement.
	During the nine months ended September 30, 2013, the Company sold a total of 14,011,526 shares of common stock under the ATM Sales Agreement. The sales were made at a weighted average price of $1.11 per share with net proceeds to the Company of $15.1 million.
	During the year ended December 31, 2012, the Company sold a total of 9,344,611 shares of common stock under the ATM Sales Agreement. The sales were made at a weighted average price of $0.59 per share with net proceeds to the Company of $5.3 million.
	Warrants
	The Company accounts for registered common stock warrants issued in July 2009, January 2011, December 2011 and March 2013 under the authoritative guidance on accounting for derivative financial instruments indexed to, and potentially settled in, a company’s own stock, on the understanding that in compliance with applicable securities laws, the registered warrants require the issuance of registered securities upon exercise and do not sufficiently preclude an implied right to net cash settlement. The Company classifies registered warrants on the condensed consolidated balance sheet as a current liability which is revalued at each balance sheet date subsequent to the initial issuance. Determining the appropriate fair-value model and calculating the fair value of registered warrants requires considerable judgment, including estimating stock price volatility and expected warrant life. The Company develops its estimates based on historical data. A small change in the estimates used may have a relatively large change in the estimated valuation. The Company uses the Black-Scholes pricing model to value the registered warrants. Changes in the fair market value of the warrants are reflected in the condensed consolidated statement of operations as “Change in fair value of common stock warrants.”
	The following table summarizes the warrants outstanding as of September 30, 2013 and December 31, 2012:
								As of September 30, 2013				As of December 31, 2012
	Issued in Connection With:		Exercise			Expiration		Number of		Common Stock		Number of	Common Stock
			Price			Date		Warrants		Warrant Liability		Warrants	Warrant Liability
	March 2013 financing		$	0.79		September 12, 2018		3,397,725		$	6,292,586	—	$	—
	December 2011 financing		$	0.65		6-Dec-16		—		—		5,774,784	2,078,921
	January 2011 financing		$	1.4		January 27, 2016		6,900,000		7,658,999		10,565,200	779,711
	July 2009 financing		$	3.38		1-Jul-14		333,333		144,233		333,333	1,267
	Warrants assumed in June 2009 Merger		$1.02-$1.28			August 1, 2015 - April 28, 2016		4,008,202		—		4,920,527	—
	Total							14,639,260		$	14,095,818	21,593,844	$	2,859,899
	During the three months ended September 30, 2013, warrants to purchase 10,290,908 shares of the Company's common stock which were issued in connection with the March 2013 financing were exercised, with proceeds to the Company of $8.2 million.
	During the three months ended September 30, 2013, warrants to purchase 5,774,784 shares of the Company's common stock which were issued in connection with the December 2011 financing were exercised, with proceeds to the Company of $3.8 million.
	During the three months ended September 30, 2013, warrants to purchase 3,665,200 shares of the Company's common stock which were issued in connection with the January 2011 financing were exercised, with proceeds to the Company of $5.1 million.
	During the nine months ended September 30, 2013, warrants expired to purchase 58,220 shares of the Company's common stock, which were assumed in the June 2009 Merger.
	In August 2012, warrants expired to purchase 150,000 shares of the Company's common stock issued in connection with consulting services received in August 2007.
	Stock Options
	The Company has one active stock and cash-based incentive plan, the Amended and Restated 2007 Omnibus Incentive Plan (the “Incentive Plan”), pursuant to which the Company has granted stock options and restricted stock awards to executive officers, directors and employees. The Incentive Plan was adopted on March 31, 2007, approved by the stockholders on May 4, 2007, approved by the stockholders as amended on May 2, 2008, and approved by the stockholders as amended and restated on August 25, 2009 and May 14, 2010. On May 14, 2010 the stockholders approved to increase the aggregate number of shares available for grant under the Incentive Plan by 2,000,000 and to provide that the aggregate number of shares available for grant under the Incentive Plan will be increased on January 1 of each year beginning in 2011 by a number of shares equal to the lesser of (1) 2,055,331 or (2) such lesser number of shares as may be determined by the Board. At September 30, 2013, the Incentive Plan reserves 11,915,993 shares of common stock for issuance as or upon exercise of incentive awards granted and to be granted at future dates. At September 30, 2013, the Company had 1,218,868 shares of common stock available for future grant under the Incentive Plan, and 240,000 shares of vested restricted stock and options to purchase 9,259,626 shares of common stock outstanding under the Incentive Plan. The awards granted and available for future grant under the Incentive Plan generally vest over three years and have a maximum contractual term of ten years. The Incentive Plan terminates by its terms on March 31, 2017.
	The Incentive Plan supersedes all of the Company’s previous stock option plans, which include the Amended 2000 Stock Option Plan and the VGX Equity Compensation Plan, under which the Company had options to purchase 1,147,999 and 6,574,572 shares of common stock outstanding at September 30, 2013, respectively. The terms and conditions of the options outstanding under these plans remain unchanged.

Net_loss_per_share

Net loss per share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Net loss per share	'
	Net loss per share
	Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of common shares outstanding during the year. Diluted loss per share is calculated in accordance with the treasury stock method and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. Since the effect of the assumed exercise of common stock options and other convertible securities was anti-dilutive for all periods presented, basic and diluted loss per share are the same.
	The following table summarizes potential common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect:
		As of September 30,
	Common Stock Equivalents	2013	2012
	Options to purchase common stock	16,982,197	16,538,985
	Warrants to purchase common stock	14,639,260	21,593,844
	Convertible preferred stock	38,233	38,233
	Total	31,659,690	38,171,062

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards expected to vest on a straight-line basis. All option grants are amortized over the requisite service period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant, commensurate with the expected life. The forfeiture rate is based on historical data, and the Company records stock-based compensation expense only for those awards that are expected to vest. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid.
	The weighted average assumptions used in the Black-Scholes model for employees and directors are presented below:
		Three Months Ended September 30,		Nine Months Ended September 30,
		2013	2012	2013	2012
	Risk-free interest rate	0.68%	0.33%	0.40%	0.36%
	Expected volatility	76%	129%	111%	131%
	Expected life in years	4	4	4	4
	Dividend yield	—	—	—	—
	Forfeiture rate	8%	8%	8%	8%
	Total employee and director compensation cost for the Company's stock plan recognized in the condensed consolidated statement of operations for the three and nine months ended September 30, 2013 was $250,000 and $920,000, respectively, of which $105,000 and $439,000 were included in research and development expenses and $145,000 and $481,000 were included in general and administrative expenses, respectively.
	Total employee and director compensation cost for the Company's stock plan recognized in the condensed consolidated statement of operations for the three and nine months ended September 30, 2012 was $253,000 and $1.0 million, respectively, of which $117,000 and $477,000 were included in research and development expenses and $136,000 and $551,000 were included in general and administrative expenses, respectively.
	At September 30, 2013, there was $1.2 million of total unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of 1.9 years.
	The weighted average grant date fair value per share was $1.31 and $0.43 for employee and director stock options granted during the three and nine months ended September 30, 2013, respectively, and $0.44 and $0.47 for employee and director stock options granted during the three and nine months ended September 30, 2012, respectively.
	The fair value of options granted to non-employees at the measurement dates were estimated using the Black-Scholes pricing model. Total stock-based compensation for options granted to non-employees for the three and nine months ended September 30, 2013 was $295,000 and $418,000, respectively. Total stock-based compensation for options granted to non-employees for the three and nine months ended September 30, 2012 was $46,000 and $149,000, respectively.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2013
Related Party Transaction, Due from (to) Related Party [Abstract]	'
Related Party Transactions	'
	Related Party Transactions
	VGX International Inc.
	The Company conducts transactions with its affiliated entity, VGX Int’l.
	On October 7, 2011, the Company entered into a Collaborative Development and License Agreement (the “Agreement”) with VGX Int’l. Under the Agreement, the Company and VGX Int’l will co-develop the Company’s SynCon® therapeutic vaccines for hepatitis B and C infections (the “Products”). Under the terms of the Agreement, VGX Int’l will receive marketing rights for the Products in Asia, excluding Japan, and in return will fully fund IND-enabling and initial Phase I and II clinical studies with respect to the Products. The Company will receive from VGX Int’l payments based on the achievement of clinical milestones and royalties based on sales of the Products in the licensed territories, retaining all commercial rights to the Products in all other territories.
	On March 24, 2010, the Company entered into a Collaboration and License Agreement (the “VGX Int’l Agreement”) with VGX Int’l. Under the VGX Int’l Agreement, the Company granted VGX Int’l an exclusive license to Inovio’s SynCon® universal influenza vaccine delivered with electroporation to be developed in certain countries in Asia (the “Product”). As consideration for the license granted to VGX Int’l, the Company received payment of $3.0 million, and will receive research support, annual license maintenance fees and royalties on net Product sales. The Company recorded the $3.0 million as deferred revenue from affiliated entity, and will recognize it as revenue over the eight year expected period of the Company’s performance obligation. In addition, contingent upon achievement of clinical and regulatory milestones, the Company will receive development payments over the term of the VGX Int’l Agreement. The VGX Int’l Agreement also provides Inovio with exclusive rights to supply devices for clinical and commercial purposes (including single use components) to VGX Int’l for use in the Product. The term of the VGX Int’l Agreement commenced upon execution and will extend on a country by country basis until the last to expire of all Royalty Periods for the territory (as such term is defined in the VGX Int’l Agreement) for any Product in that country, unless the VGX Int’l Agreement is terminated earlier in accordance with its provisions as a result of breach, by mutual agreement, or by VGX Int’l’s right to terminate without cause upon prior written notice.
	For the three and nine months ended September 30, 2013, the Company recognized revenue from VGX Int'l of $106,000 and $319,000, respectively, which consisted of licensing and other fees. Operating expenses related to VGX Int'l for the three and nine months ended September 30, 2013 include $402,000 and $960,000 respectively, related to biologics manufacturing. At September 30, 2013 and December 31, 2012 we had an accounts receivable balance of $0 and $36,000, respectively, from VGX Int'l and its subsidiaries. For the three and nine months ended September 30, 2012, the Company recognized revenue from VGX Int'l of $222,000 and $435,000, respectively, which consisted of licensing fees. Operating expenses related to VGX Int'l for the three and nine months ended September 30, 2012 include $288,000 and $616,000, respectively, related to biologics manufacturing and engineering services.
	Prior to signing the Roche Agreement, the Company reacquired the rights, title and interest to hepatitis B in Asia previously licensed to VGX Int'l. As a result, the Company has recorded a liability as of September 30, 2013 of approximately $300,000, related to sub-license fees payable to VGX Int'l based on our up-front payment received from Roche.
	OncoSec Medical Incorporated
	On March 24, 2011, the Company completed the sale of certain assets related to certain non-DNA vaccine technology and intellectual property relating to selective electrochemical tumor ablation (“SECTA”) to OncoSec Medical Incorporated, or OncoSec, pursuant to an Asset Purchase Agreement dated March 14, 2011 by and between the Company and OncoSec.
	The Company's Chairman, Dr. Avtar Dhillon, is the non-executive Chairman of OncoSec.
	The Company has received total payment of $2.0 million from OncoSec through September 30, 2013, including $1.0 million received during the quarter ended June 30, 2013, and will receive an additional $1.0 million in scheduled payments over a period of approximately three years from the closing date and a royalty on any potential commercial product sales related to the SECTA technology if and when a product is approved. No receivable has been recorded for the $1.0 million due from OncoSec as collection is uncertain.
	On September 28, 2011, the Company signed an amended agreement with OncoSec extending the term of the second payment owed to the Company in exchange for a warrant to purchase 1,000,000 shares of common stock of OncoSec. The warrant received was a five-year warrant with an exercise price of $1.20 per share. (See Note 6 for further discussion.)
	On March 24, 2012, the Company signed a second amended agreement with OncoSec further extending the term of the payments owed to the Company in exchange for a warrant to purchase 3,000,000 shares of common stock of OncoSec. The warrant received was a five-year warrant with an exercise price of $1.00 per share. (See Note 6 for further discussion.)

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	In April 2013, the Company entered into an office lease (the “Lease”) with BMR-Wateridge LP, located in San Diego, California. The lease requires the lessor to complete and pay for certain improvements to the building before the commencement of the lease which is estimated to be in the fourth quarter of 2013. As of September 30, 2013 the lessor has completed approximately $1.8 million of these improvements. This amount has been recorded as a leasehold improvement within fixed assets on the condensed consolidated balance sheet, offset by a corresponding amount recorded in deferred rent. The initial term of the Lease is ten years. The Company intends to use the facility for office and research and development purposes.
	The base rent adjusts periodically throughout the ten year term of the Lease, with monthly payments ranging from zero to $82,945. In addition, the Company will pay the landlord our share of operating expenses and a property management fee and has paid a security deposit of $64,000.

Roche_Collaboration_Option_and

Roche Collaboration, Option and License Agreement	9 Months Ended
	Sep. 30, 2013
Research and Development [Abstract]	'
Roche Collaboration, Option and License Agreement	'
	Roche Collaboration, Option and License Agreement
	In September 2013, the Company entered into a Collaborative, License, and Option Agreement (the “Agreement”) with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (“Roche”). Under the Agreement, the Company and Roche will co-develop highly-optimized, multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B (the “Products”).
	Roche acquired an exclusive worldwide license for the Company's DNA-based vaccines INO-5150 (targeting prostate cancer) and INO-1800 (targeting hepatitis B) as well as the use of the Company's CELLECTRA® electroporation technology for delivery of the vaccines. Roche also obtained an option to license additional vaccines in connection with a collaborative research program in prostate cancer.
	Under the terms of the Agreement, Roche made an upfront payment of $10 million and has agreed to make additional development, regulatory and commercial event based payments of up to $412.5 million. Additional event based payments could also be made to the Company if Roche pursues other indications with INO-5150 or INO-1800. Of these event based payments, we expect to achieve up to $5.0 million and $3.0 million related to INO-5150 and INO-1800, respectively, in the next two fiscal years. No event based payments or milestones were achieved during the periods presented.
	The Company is entitled to receive up to double-digit tiered royalties on product sales. Unless terminated earlier in accordance with its terms, the Agreement continues in effect until the date when no royalty or other payment obligations under the Agreement are or will become due, i.e., a royalty term ending on the later of the date that is (a) ten years after the date of the first commercial sale of the product that is subject to the Agreement or (b) the expiration of the last to expire of our patent rights that are subject to the Agreement. Under the terms of the Agreement we also agreed to perform certain research and development and manufacturing and supply services, at Roche's expense.
	The Company identified the deliverables at the inception of the agreement. The Company has determined that the license to INO-5150 and INO-1800, the Option Right to license additional vaccines, research and development services, manufacturing and drug supply, and participation in the Joint Steering Committee individually represent separate units of accounting because each deliverable has standalone value. The best estimated selling prices for these units of accounting were determined based on market conditions, the terms of comparable collaborative agreements for similar technology in the pharmaceutical and biotechnology industry, the Company's pricing practices and pricing objectives and the nature of the research and development services to be provided. While market data was considered throughout the valuation process, ultimately, the selling prices of the licenses were determined utilizing two forms of the relief from royalty method under the Income Approach and the cost-to-recreate method under the Cost Approach. The arrangement consideration was allocated to the deliverables based on the relative selling price method.
	The amount allocable to the delivered unit or units of accounting is limited to the amount that is not contingent upon the delivery of additional items or meeting other specified performance conditions. Based on the results of the Company's analysis, the $10 million up-front payment was allocated as follows: $5 million and $3.4 million to the license to INO-5150 and INO-1800, respectively, and $1.5 million to the Option Right. The amounts allocated to the licenses to INO-5150 and INO-1800 were recognized as license fee and milestone revenue during the three and nine months ended September 30, 2013, as these were determined to be earned upon the granting and delivery of the licenses. Due to the Company's continuing involvement obligations, the remaining amounts will be classified as deferred revenue as of September 30, 2013. The Company will recognize expenses related to research and development services and manufacturing and drug supply as revenues under collaborative agreements as the related services are performed.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	Subsequent Events
	Subsequent to September 30, 2013, Roche made the upfront payment of $10.0 million to the Company due from the Collaboration, Option and License Agreement.
	Subsequent to September 30, 2013, the Company sold 348,995 shares of common stock under its ATM Sales Agreement for net proceeds of $782,000.
	Subsequent to September 30, 2013, warrants to purchase 375,000 shares of common stock were exercised for total proceeds to the Company of $298,000.

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of September 30, 2013, condensed consolidated statements of operations for the three and nine months ended September 30, 2013 and 2012, condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2013 and 2012 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2013 and 2012, are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented. The results of operations for the three and nine months ended September 30, 2013 shown herein are not necessarily indicative of the results that may be expected for the year ending December 31, 2013, or for any other period. These financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2012, included in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on March 18, 2013. The balance sheet at December 31, 2012 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The Company has evaluated subsequent events after the balance sheet date of September 30, 2013 through the date it filed these unaudited condensed consolidated financial statements with the SEC.
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	The Company incurred a net loss of $30.9 million and $50.6 million, respectively, for the three and nine months ended September 30, 2013. The Company had working capital of $37.4 million and an accumulated deficit of $280.3 million as of September 30, 2013. The Company’s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These unaudited interim condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should the Company be unable to continue in business. The Company's unaudited interim condensed consolidated financial statements as of and for the period ended September 30, 2013 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future.

Investments_Tables

Investments (Tables)	9 Months Ended
	Sep. 30, 2013
Investments, Debt and Equity Securities [Abstract]	'
Summary of investments	'
	The following is a summary of investments as of September 30, 2013 and December 31, 2012:
			As of September 30, 2013
		Contractual	Cost		Gross Unrealized		Gross Unrealized			Fair Market Value
		Maturity (in years)			Gains		Losses
	Mutual funds	Less than 1	$	13,191,964	$	—	$	(87,101	)	$	13,104,863
	Total investments		$	13,191,964	$	—	$	(87,101	)	$	13,104,863
			As of December 31, 2012
		Contractual	Cost		Gross Unrealized		Gross Unrealized			Fair Market Value
		Maturity (in years)			Gains		Losses
	Mutual funds	Less than 1	$	7,500,063	$	83,868	$	—		$	7,583,931
	Certificates of deposit	Less than 1	250,000		—		—			250,000
	Municipal bonds	Less than 1	201,470		—		(1,400		)	200,070
	Total investments		$	7,951,533	$	83,868	$	(1,400	)	$	8,034,001

Marketable_Securities_and_Fair1

Marketable Securities and Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Financial assets and liabilities measured at fair value on a recurring basis	'
	The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2013:
		Fair Value Measurements at
		September 30, 2013
		Total			Using Quoted Prices		Using Significant		Using Significant
					in Active Markets		Other Unobservable		Unobservable
					for Identical Assets		Inputs		Inputs
					(Level 1)		(Level 2)		(Level 3)
	Assets:
	Money market funds	$	18,338,897		$	18,338,897	$	—	$	—
	Mutual funds	13,104,863			—		13,104,863		—
	Investment in affiliated entity	11,084,123			11,084,123		—		—
	Common stock warrants	244,900			—		—		244,900
	Total Assets	$	42,772,783		$	29,423,020	$	13,104,863	$	244,900
	Liabilities:
	Common stock warrants	$	14,095,818		$	—	$	—	$	14,095,818
	Total Liabilities	$	14,095,818		$	—	$	—	$	14,095,818
	The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2012:
		Fair Value Measurements at
		December 31, 2012
		Total			Using Quoted Prices		Using Significant		Using Significant
					in Active Markets		Other Unobservable		Unobservable
					for Identical Assets		Inputs		Inputs
					(Level 1)		(Level 2)		(Level 3)
	Assets:
	Money market funds	$	1,686,406		$	1,686,406	$	—	$	—
	Mutual funds	7,583,931			—		7,583,931		—
	Certificates of deposit	250,000			—		250,000		—
	Municipal bonds	200,070			—		200,070		—
	Investment in affiliated entity	10,703,332			10,703,332		—		—
	Common stock warrants	267,200			—		—		267,200
	Total Assets	$	20,690,939		$	12,389,738	$	8,034,001	$	267,200
	Liabilities:
	Common stock warrants	$	2,859,899		$	—	$	—	$	2,859,899
	Total Liabilities	$	2,859,899		$	—	$	—	$	2,859,899
Assumptions used to estimate the fair values of the common stock warrants	'
	The range of assumptions used to estimate the fair values of common stock warrants at September 30, 2013 are presented below:
	Risk-free interest rate	0.13%-1.52%
	Expected volatility	88%-119%
	Expected life in years	0.75-4.96
	Dividend yield	—
Change in fair value of the financial assets	'
	The following table presents a summary of changes in fair value of the Company’s total Level 3 financial assets for the nine months ended September 30, 2013:
	Balance at January 1, 2013	$	267,200
	Decrease in fair value included in change in fair value of common stock warrants	(22,300		)
	Balance at September 30, 2013	$	244,900
Changes in fair value of the financial liabilities	'
	The following table presents the changes in fair value of the Company’s total Level 3 financial liabilities for the nine months ended September 30, 2013:
	Balance at January 1, 2013	$	2,859,899
	Record fair value of warrants issued in March 2013 financing	5,968,244
	Increase in fair value included in change in fair value of common stock warrants	39,557,404
	Change in classification from liability to stockholders' equity due to warrant exercises	(34,289,729		)
	Balance at September 30, 2013	$	14,095,818
OncoSec [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Assumptions used to estimate the fair values of the common stock warrants	'
	The assumptions used to estimate the fair values of the OncoSec common stock warrants at September 30, 2013 are presented below:
	Risk-free interest rate	0.63%
	Expected volatility	85%
	Expected life in years	3-3.5
	Dividend yield	—

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Summary of intangible assets by major asset class	'
	The following sets forth the goodwill and intangible assets by major asset class:
			September 30, 2013							December 31, 2012
		Useful	Gross		Accumulated			Net Book		Gross		Accumulated			Net Book
		Life			Amortization			Value				Amortization			Value
		(Yrs)
	Non-Amortizing:
	Goodwill(a)		$	10,113,371	$	—		$	10,113,371	$	10,113,371	$	—		$	10,113,371
	Amortizing:
	Patents	8 – 17	5,802,528		(5,064,115		)	738,413		5,802,528		(4,852,673		)	949,855
	Licenses	8 – 17	1,323,761		(1,068,431		)	255,330		1,323,761		(1,046,870		)	276,891
	CELLECTRA®(b)	5 – 11	8,106,270		(5,241,398		)	2,864,872		8,106,270		(4,334,234		)	3,772,036
	GHRH(b)	11	335,314		(137,294		)	198,020		335,314		(113,531		)	221,783
	Other(c)	18	4,050,000		(1,950,000		)	2,100,000		4,050,000		(1,781,250		)	2,268,750
	Total intangible assets		19,617,873		(13,461,238		)	6,156,635		19,617,873		(12,128,558		)	7,489,315
	Total goodwill and intangible assets		$	29,731,244	$	(13,461,238	)	$	16,270,006	$	29,731,244	$	(12,128,558	)	$	17,602,686
	(a)	Goodwill was recorded from the Inovio AS acquisition in January 2005 and from the acquisition of VGX in June 2009 for $3.9 million and $6.2 million, respectively.
	(b)	CELLECTRA® and GHRH are developed technologies which were recorded from the acquisition of VGX.
	(c)	Other intangible assets represent the fair value of acquired contracts and intellectual property from the Inovio AS acquisition.

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Summary of preferred stock authorized, issued and outstanding	'
	The following is a summary of the Company's authorized and issued common and preferred stock as of September 30, 2013 and December 31, 2012:
							Outstanding as of
		Authorized			Issued		September 30,		December 31,
							2013		2012
	Common Stock, par $0.001	600,000,000			207,620,037		207,620,037		144,313,005
	Series A Preferred Stock, par $0.001	1,000			817		—		—
	Series B Preferred Stock, par $0.001	1,000			750		—		—
	Series C Preferred Stock, par $0.001	1,091			1,091		26		26
	Series D Preferred Stock, par $0.001	1,966,292			1,966,292		—		—
Summary of warrants outstanding	'
	The following table summarizes the warrants outstanding as of September 30, 2013 and December 31, 2012:
								As of September 30, 2013				As of December 31, 2012
	Issued in Connection With:		Exercise			Expiration		Number of		Common Stock		Number of	Common Stock
			Price			Date		Warrants		Warrant Liability		Warrants	Warrant Liability
	March 2013 financing		$	0.79		September 12, 2018		3,397,725		$	6,292,586	—	$	—
	December 2011 financing		$	0.65		6-Dec-16		—		—		5,774,784	2,078,921
	January 2011 financing		$	1.4		January 27, 2016		6,900,000		7,658,999		10,565,200	779,711
	July 2009 financing		$	3.38		1-Jul-14		333,333		144,233		333,333	1,267
	Warrants assumed in June 2009 Merger		$1.02-$1.28			August 1, 2015 - April 28, 2016		4,008,202		—		4,920,527	—
	Total							14,639,260		$	14,095,818	21,593,844	$	2,859,899

Net_loss_per_share_Tables

Net loss per share (Tables)	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	'
	The following table summarizes potential common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect:
		As of September 30,
	Common Stock Equivalents	2013	2012
	Options to purchase common stock	16,982,197	16,538,985
	Warrants to purchase common stock	14,639,260	21,593,844
	Convertible preferred stock	38,233	38,233
	Total	31,659,690	38,171,062

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of weighted average assumptions	'
	The weighted average assumptions used in the Black-Scholes model for employees and directors are presented below:
		Three Months Ended September 30,		Nine Months Ended September 30,
		2013	2012	2013	2012
	Risk-free interest rate	0.68%	0.33%	0.40%	0.36%
	Expected volatility	76%	129%	111%	131%
	Expected life in years	4	4	4	4
	Dividend yield	—	—	—	—
	Forfeiture rate	8%	8%	8%	8%

Basis_of_Presentation_Details

Basis of Presentation (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Basis of Presentation [Abstract]	'	'	'	'	'
Net loss from operations	($30,877,410)	($6,622,076)	($50,574,118)	($19,010,204)	'
Working capital	37,400,000	'	37,400,000	'	'
Accumulated deficit	($280,334,247)	'	($280,334,247)	'	($229,760,129)

Principles_of_Consolidation_De

Principles of Consolidation (Details)	Sep. 30, 2013	Dec. 31, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'
Noncontrolling interest, ownership percentage by parent	88.00%	'
Noncontrolling interest, ownership percentage by noncontrolling owners	9.00%	9.00%

Investments_Details

Investments (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Summary of investments	'	'
Cost	13,191,964	7,951,533
Gross Unrealized Gains	0	83,868
Gross Unrealized Losses	-87,101	-1,400
Fair Market Value	13,104,863	8,034,001
Mutual funds [Member]	'	'
Summary of investments	'	'
Cost	13,191,964	7,500,063
Gross Unrealized Gains	0	83,868
Gross Unrealized Losses	-87,101	0
Fair Market Value	13,104,863	7,583,931
Certificates of deposit [Member]	'	'
Summary of investments	'	'
Cost	'	250,000
Gross Unrealized Gains	'	0
Gross Unrealized Losses	'	0
Fair Market Value	'	250,000
Municipal bonds [Member]	'	'
Summary of investments	'	'
Cost	'	201,470
Gross Unrealized Gains	'	0
Gross Unrealized Losses	'	-1,400
Fair Market Value	'	200,070
Maximum [Member] | Mutual funds [Member]	'	'
Summary of investments	'	'
Contractual maturity, less than	'1 year	'1 year
Maximum [Member] | Certificates of deposit [Member]	'	'
Summary of investments	'	'
Contractual maturity, less than	'	'1 year
Maximum [Member] | Municipal bonds [Member]	'	'
Summary of investments	'	'
Contractual maturity, less than	'	'1 year

Investments_Details_Textual

Investments (Details Textual) (USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2013
Investments (Textual) [Abstract]	'	'
Other than temprory impairment losses	$0	$0

Marketable_Securities_and_Fair2

Marketable Securities and Fair Value Measurements (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Sep. 30, 2013	Dec. 31, 2012
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	$42,772,783	$20,690,939
Liabilities, fair value	14,095,818	2,859,899
Using Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	29,423,020	12,389,738
Liabilities, fair value	0	0
Using Significant Other Unobservable Inputs (Level 2) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	13,104,863	8,034,001
Liabilities, fair value	0	0
Using Significant Unobservable Inputs (Level 3) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	244,900	267,200
Liabilities, fair value	14,095,818	2,859,899
Money market funds [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	18,338,897	1,686,406
Money market funds [Member] | Using Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	18,338,897	1,686,406
Money market funds [Member] | Using Significant Other Unobservable Inputs (Level 2) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	0	0
Money market funds [Member] | Using Significant Unobservable Inputs (Level 3) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	0	0
Mutual funds [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	13,104,863	7,583,931
Mutual funds [Member] | Using Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	0	0
Mutual funds [Member] | Using Significant Other Unobservable Inputs (Level 2) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	13,104,863	7,583,931
Mutual funds [Member] | Using Significant Unobservable Inputs (Level 3) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	0	0
Certificates of deposit [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	'	250,000
Certificates of deposit [Member] | Using Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	'	0
Certificates of deposit [Member] | Using Significant Other Unobservable Inputs (Level 2) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	'	250,000
Certificates of deposit [Member] | Using Significant Unobservable Inputs (Level 3) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	'	0
Municipal bonds [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	'	200,070
Municipal bonds [Member] | Using Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	'	0
Municipal bonds [Member] | Using Significant Other Unobservable Inputs (Level 2) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	'	200,070
Municipal bonds [Member] | Using Significant Unobservable Inputs (Level 3) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	'	0
Investment in affiliated entity [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	11,084,123	10,703,332
Investment in affiliated entity [Member] | Using Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	11,084,123	10,703,332
Investment in affiliated entity [Member] | Using Significant Other Unobservable Inputs (Level 2) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	0	0
Investment in affiliated entity [Member] | Using Significant Unobservable Inputs (Level 3) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	0	0
Common stock warrants [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	244,900	267,200
Liabilities, fair value	14,095,818	2,859,899
Common stock warrants [Member] | Using Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	0	0
Liabilities, fair value	0	0
Common stock warrants [Member] | Using Significant Other Unobservable Inputs (Level 2) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	0	0
Liabilities, fair value	0	0
Common stock warrants [Member] | Using Significant Unobservable Inputs (Level 3) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	244,900	267,200
Liabilities, fair value	$14,095,818	$2,859,899

Marketable_Securities_and_Fair3

Marketable Securities and Fair Value Measurements (Details 1) (USD $)	9 Months Ended
	Sep. 30, 2013
Assumptions used to estimate the fair values of the common stock warrants	'
Dividend yield	$0
Minimum [Member]	'
Assumptions used to estimate the fair values of the common stock warrants	'
Risk-free interest rate	0.13%
Expected volatility	88.00%
Expected life	'9 months
Maximum [Member]	'
Assumptions used to estimate the fair values of the common stock warrants	'
Risk-free interest rate	1.52%
Expected volatility	119.00%
Expected life	'4 years 11 months 16 days
OncoSec common stock warrants [Member]	'
Assumptions used to estimate the fair values of the common stock warrants	'
Risk-free interest rate	0.63%
Expected volatility	85.00%
Dividend yield	$0
OncoSec common stock warrants [Member] | Minimum [Member]	'
Assumptions used to estimate the fair values of the common stock warrants	'
Expected life	'3 years
OncoSec common stock warrants [Member] | Maximum [Member]	'
Assumptions used to estimate the fair values of the common stock warrants	'
Expected life	'3 years 6 months

Marketable_Securities_and_Fair4

Marketable Securities and Fair Value Measurements (Details 2) (Using Significant Unobservable Inputs (Level 3) [Member], USD $)	9 Months Ended
	Sep. 30, 2013
Using Significant Unobservable Inputs (Level 3) [Member]	'
Change in fair value of the financial assets	'
Balance at beginning of year	$267,200
Decrease in fair value included in change in fair value of common stock warrants	-22,300
Balance at end of year	$244,900

Marketable_Securities_and_Fair5

Marketable Securities and Fair Value Measurements (Details 3) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Changes in fair value of the financial liabilities	'	'	'	'
Increase in fair value included in change in fair value of common stock warrants	$34,900,000	$1,100,000	$39,600,000	$987,000
Using Significant Unobservable Inputs (Level 3) [Member]	'	'	'	'
Changes in fair value of the financial liabilities	'	'	'	'
Balance at January 1, 2013	'	'	2,859,899	'
Record fair value of warrants issued	'	'	5,968,244	'
Increase in fair value included in change in fair value of common stock warrants	'	'	39,557,404	'
Change in classification from liability to stockholders' equity due to warrant exercises	'	'	-34,289,729	'
Balance at September 30, 2013	$14,095,818	'	$14,095,818	'

Marketable_Securities_and_Fair6

Marketable Securities and Fair Value Measurements (Details Textual) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

1 Months Ended

Mar. 31, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2011

Mar. 31, 2012

Onco Sec Common Stock Warrants [Member]

Onco Sec Common Stock Warrants [Member]

Onco Sec Common Stock Warrants [Member]

Onco Sec Common Stock Warrants [Member]

Using Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]

Using Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]

Using Significant Unobservable Inputs (Level 3) [Member]

Using Significant Unobservable Inputs (Level 3) [Member]

Using Significant Unobservable Inputs (Level 3) [Member]

warrant

First warrant [Member]

Second warrant [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Warrants Exercised

'

'

'

20,584,997

'

'

'

'

'

'

'

'

'

'

'

Marketable Securities and Fair Value Measurements (Textual) [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares held in an affiliated entity

'

'

'

'

'

'

'

'

'

'

8,220,775

8,220,775

'

'

'

Number of warrants received to purchase shares of common stock

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

Common stock purchase warrant

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

3,000,000

Term of the warrants in years

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'5 years

Exercise price of a five-year warrant

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.20

$1

Long-term asset associated with warrants

'

$245,000

'

$245,000

'

'

'

'

'

'

'

'

'

'

'

Gain on sale of asset

501,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Change in the fair value

'

34,900,000

1,100,000

39,600,000

987,000

'

-21,000

11,000

-22,000

-80,000

'

'

39,557,404

'

'

Common stock warrants

'

$14,095,818

'

$14,095,818

'

$2,859,899

'

'

'

'

'

'

'

'

'

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets (Details) (USD $)

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Jan. 31, 2005

Jun. 30, 2009

Patents [Member]

Patents [Member]

Patents [Member]

Patents [Member]

Licences [Member]

Licences [Member]

Licences [Member]

Licences [Member]

CELLECTRA [Member]

CELLECTRA [Member]

CELLECTRA [Member]

CELLECTRA [Member]

GHRH [Member]

GHRH [Member]

Other [Member]

Other [Member]

Inovio AS [Member]

VGX [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Schedule of intangible assets by major asset class

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Useful Life

'

'

'

'

'8 years

'17 years

'

'

'8 years

'17 years

'

'

'5 years

[1]

'11 years

[1]

'11 years

[1]

'

'18 years

[2]

'

'

'

Non-Amortizing:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill, Gross

$10,113,371

[3]

$10,113,371

[3]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill, Net Book Value

10,113,371

[3]

10,113,371

[3]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,900,000

6,200,000

Amortizing:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible assets, Gross

19,617,873

19,617,873

5,802,528

5,802,528

'

'

1,323,761

1,323,761

'

'

8,106,270

[1]

8,106,270

[1]

'

'

335,314

[1]

335,314

[1]

4,050,000

[2]

4,050,000

[2]

'

'

Intangible assets, Accumulated Amortization

-13,461,238

-12,128,558

-5,064,115

-4,852,673

'

'

-1,068,431

-1,046,870

'

'

-5,241,398

[1]

-4,334,234

[1]

'

'

-137,294

[1]

-113,531

[1]

-1,950,000

[2]

-1,781,250

[2]

'

'

Intangible assets, Net Book Value

6,156,635

7,489,315

738,413

949,855

'

'

255,330

276,891

'

'

2,864,872

[1]

3,772,036

[1]

'

'

198,020

[1]

221,783

[1]

2,100,000

[2]

2,268,750

[2]

'

'

Total goodwill and intangible assets, Gross

29,731,244

29,731,244

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total goodwill and intangible assets, Net Book Value

$16,270,006

$17,602,686

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

CELLECTRAB. and GHRH are developed technologies which were recorded from the acquisition of VGX.

[2]

Other intangible assets represent the fair value of acquired contracts and intellectual property from the Inovio AS acquisition.

[3]

Goodwill was recorded from the Inovio AS acquisition in January 2005 and from the acquisition of VGX in June 2009 for $3.9 million and $6.2 million, respectively.

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets (Details 1) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Goodwill and Intangible Assets (Textual) [Abstract]	'	'	'	'
Aggregate amortization expense on intangible assets	$440,000	$453,000	$1,332,680	$1,370,744
Estimated aggregate amortization expense for remainder of 2013	438,000	'	438,000	'
Estimated aggregate amortization expense for 2014	943,000	'	943,000	'
Estimated aggregate amortization expense for 2015	870,000	'	870,000	'
Estimated aggregate amortization expense for 2016	816,000	'	816,000	'
Estimated aggregate amortization expense for 2017	775,000	'	775,000	'
Estimated aggregate amortization expense for 2018	$773,000	'	$773,000	'

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	Sep. 30, 2013	31-May-13	Apr. 30, 2013	Dec. 31, 2012	Sep. 30, 2012
Summary of common and preferred stock authorized, issued and outstanding	'	'	'	'	'
Common stock, shares authorized	600,000,000	600,000,000	300,000,000	'	300,000,000
Common stock, shares, issued	207,620,037	'	'	'	179,940,861
Common stock, shares, outstanding	207,620,037	'	'	144,313,005	'
Common stock, par value (Dollars per share)	$0.00	'	'	'	$0.00
Series A Preferred Stock [Member]	'	'	'	'	'
Summary of common and preferred stock authorized, issued and outstanding	'	'	'	'	'
Preferred Stock, par value (Dollars per share)	$0.00	'	'	0.001	'
Preferred stock, shares authorized	1,000	'	'	1,000	'
Preferred stock, shares issued	817	'	'	817	'
Preferred stock, shares outstanding	0	'	'	0	'
Series B Preferred Stock [Member]	'	'	'	'	'
Summary of common and preferred stock authorized, issued and outstanding	'	'	'	'	'
Preferred Stock, par value (Dollars per share)	$0.00	'	'	0.001	'
Preferred stock, shares authorized	1,000	'	'	1,000	'
Preferred stock, shares issued	750	'	'	750	'
Preferred stock, shares outstanding	0	'	'	0	'
Series C Preferred Stock [Member]	'	'	'	'	'
Summary of common and preferred stock authorized, issued and outstanding	'	'	'	'	'
Preferred Stock, par value (Dollars per share)	$0.00	'	'	0.001	'
Preferred stock, shares authorized	1,091	'	'	1,091	'
Preferred stock, shares issued	1,091	'	'	1,091	'
Preferred stock, shares outstanding	26	'	'	26	'
Series D Preferred Stock [Member]	'	'	'	'	'
Summary of common and preferred stock authorized, issued and outstanding	'	'	'	'	'
Preferred Stock, par value (Dollars per share)	$0.00	'	'	0.001	'
Preferred stock, shares authorized	1,966,292	'	'	1,966,292	'
Preferred stock, shares issued	1,966,292	'	'	1,966,292	'
Preferred stock, shares outstanding	0	'	'	0	'

Stockholders_Equity_Details_1

Stockholders' Equity (Details 1) (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Summary of warrants outstanding	'	'
Number of Warrants	14,639,260	21,593,844
Common Stock Warrant Liability	$14,095,818	$2,859,899
March 2013 Financing [Member]	'	'
Summary of warrants outstanding	'	'
Exercise Price	0.79	'
Expiration Date	12-Sep-18	'
Number of Warrants	3,397,725	0
Common Stock Warrant Liability	6,292,586	0
December 2011 financing [Member]	'	'
Summary of warrants outstanding	'	'
Exercise Price	0.65	'
Expiration Date	6-Dec-16	'
Number of Warrants	0	5,774,784
Common Stock Warrant Liability	0	2,078,921
January 2011 financing [Member]	'	'
Summary of warrants outstanding	'	'
Exercise Price	1.4	'
Expiration Date	27-Jan-16	'
Number of Warrants	6,900,000	10,565,200
Common Stock Warrant Liability	7,658,999	779,711
July 2009 financing [Member]	'	'
Summary of warrants outstanding	'	'
Exercise Price	3.38	'
Expiration Date	1-Jul-14	'
Number of Warrants	333,333	333,333
Common Stock Warrant Liability	144,233	1,267
Warrants assumed in June 2009 Merger [Member]	'	'
Summary of warrants outstanding	'	'
Number of Warrants	4,008,202	4,920,527
Common Stock Warrant Liability	$0	$0
Minimum [Member] | Warrants assumed in June 2009 Merger [Member]	'	'
Summary of warrants outstanding	'	'
Exercise Price	1.02	'
Expiration Date	1-Aug-15	'
Maximum [Member] | Warrants assumed in June 2009 Merger [Member]	'	'
Summary of warrants outstanding	'	'
Exercise Price	1.28	'
Expiration Date	28-Apr-16	'

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)

9 Months Ended

0 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

12 Months Ended

3 Months Ended

Sep. 30, 2013

Sep. 30, 2012

31-May-13

Apr. 30, 2013

Dec. 31, 2012

14-May-10

Sep. 30, 2013

Sep. 30, 2013

Aug. 31, 2012

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Sep. 30, 2013

Jun. 30, 2012

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Stock and Cash Based Incentive Plan [Member]

Stock and Cash Based Incentive Plan [Member]

Amended 2000 Stock Option Plan [Member]

Common Stock Warrants [Member]

Common Stock Warrants [Member]

Underwritten public offering [Member]

Underwritten public offering [Member]

Underwritten public offering [Member]

Sales Agreement [Member]

Sales Agreement [Member]

VGX Equity Compensation Plan [Member]

March 2013 Financing [Member]

December 2011 financing [Member]

January 2011 financing [Member]

Stockholders' Equity (Textual) [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares authorized

600,000,000

300,000,000

600,000,000

300,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, capital shares reserved for future issuance

'

'

'

'

'

'

'

'

'

'

27,377,266

'

'

'

'

'

'

'

'

Common stock purchase warrant

'

'

'

'

'

'

'

'

'

'

13,688,633

'

'

'

'

'

'

'

'

Purchase price per unit of common stock and warrant

'

'

'

'

'

'

'

'

'

'

0.55

'

'

'

'

'

'

'

'

Class of warrant or right, number of securities called by each warrant or right

'

'

'

'

'

'

'

'

'

'

0.5

'

'

'

'

'

'

'

'

Class of warrant or right, securities called by warrants or rights, price per share

'

'

'

'

'

'

'

'

'

'

$0.79

'

'

'

'

'

'

'

'

Term of the warrants in years

'

'

'

'

'

'

'

'

'

'

'5 years 6 months

'

'

'

'

'

'

'

'

Potential proceeds from issue of common stock

'

'

'

'

'

'

'

'

'

'

$14,000,000

'

'

'

'

'

'

'

'

Warrants, Fair Value Disclosure

'

'

'

'

'

'

'

'

'

'

6,000,000

'

'

'

'

'

'

'

'

Increase in fair value of warrants

'

'

'

'

'

'

'

'

'

'

'

19,600,000

22,700,000

'

'

'

'

'

'

Stock Issued During Period, Shares, Warrants Exercised

20,584,997

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,290,908

5,774,784

3,665,200

Transaction costs associated with issuance of warrants

315,970

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Potential proceeds from sale of common stock through placement agent for resale

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000,000

'

'

'

'

'

Rate of commission or discount to placement agent

'

'

'

'

'

'

'

'

'

'

'

'

'

3.00%

'

'

'

'

'

Common stock sold under sales agreement

14,011,526

'

'

'

'

'

'

'

'

'

'

'

'

'

9,344,611

'

'

'

'

Weighted average price per share on sale of common stock

$1.11

'

'

'

$0.59

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of common stock and warrants

$15,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,300,000

'

$8,200,000

$3,800,000

$5,100,000

Warrants expired to purchase number of shares of common stock

'

'

'

'

'

'

'

'

150,000

58,220

'

'

'

'

'

'

'

'

'

Number of additional shares authorized

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of potential shares authorized for issuance under share based compensation plan

'

'

'

'

'

2,055,331

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares authorized

'

'

'

'

'

'

11,915,993

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares available for grant

'

'

'

'

'

'

1,218,868

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares of vested restricted stock outstanding under plan

'

'

'

'

'

'

240,000

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, other shares, outstanding

'

'

'

'

'

'

9,259,626

'

'

'

'

'

'

'

'

'

'

'

'

Award vesting period

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum contractual term

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options, outstanding, number

'

'

'

'

'

'

'

1,147,999

'

'

'

'

'

'

'

6,574,572

'

'

'

Net_loss_per_share_Details

Net loss per share (Details)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share, amount	31,659,690	38,171,062
Stock Options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share, amount	16,982,197	16,538,985
Warrant [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share, amount	14,639,260	21,593,844
Convertible Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share, amount	38,233	38,233

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation	'	'	$1,338,427	$1,176,874
Total unrecognized compensation cost related to unvested stock options	1,200,000	'	1,200,000	'
Period over which total unrecognized compensation cost related to unvested stock options will be recognized	'1 year 11 months 6 days	'	'	'
Weighted average grant date fair value per share	$1.31	$0.44	$0.43	$0.47
Employees and Directors [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation	250,000	253,000	920,000	1,000,000
Employees and Directors [Member] | Stock Options [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Risk-free interest rate	0.68%	0.33%	0.40%	0.36%
Expected volatility	76.00%	129.00%	111.00%	131.00%
Expected life	'4 years	'4 years	'4 years	'4 years
Dividend yield	0.00%	0.00%	0.00%	0.00%
Forfeiture Rate	8.00%	8.00%	8.00%	8.00%
Non Employee [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation	295,000	46,000	418,000	149,000
Research and Development Expense [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Allocated share-based compensation expense	105,000	117,000	439,000	477,000
General and Administrative Expense [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Allocated share-based compensation expense	$145,000	$136,000	$481,000	$551,000

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)

Sep. 30, 2013

Dec. 31, 2012

Mar. 24, 2010

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 30, 2013

Jun. 30, 2013

Sep. 28, 2011

Mar. 24, 2012

VGX Int'l [Member]

VGX Int'l [Member]

VGX Int'l [Member]

VGX Int'l [Member]

VGX Int'l [Member]

VGX Int'l [Member]

OncoSec [Member]

OncoSec [Member]

OncoSec [Member]

OncoSec [Member]

First warrant [Member]

Second warrant [Member]

Related-Party Transactions (Textual) [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

Payment received for license granted

'

'

$3,000,000

'

'

'

'

'

'

'

'

'

Deferred revenue from affiliated entity

'

'

3,000,000

'

'

'

'

'

'

'

'

'

Period over which deferred revenue from affiliated entity will be recognized in years

'

'

'8 years

'

'

'

'

'

'

'

'

'

Revenue from related parties

'

'

'

106,000

222,000

319,000

435,000

'

'

'

'

'

Operating expenses related to affiliated entity

'

'

'

402,000

288,000

960,000

616,000

'

'

'

'

'

Accounts receivable from related parties

'

'

'

0

'

0

'

36,000

'

'

'

'

Amount payable to related party

'

'

'

300,000

'

300,000

'

'

'

'

'

'

Payments received from affiliate

'

'

'

'

'

'

'

'

2,000,000

1,000,000

'

'

Additional future scheduled payments from affiliated entity

'

'

'

'

'

'

'

'

1,000,000

'

'

'

Term of future scheduled payments from affiliated entity

'

'

'

'

'

'

'

'

'3 years

'

'

'

Receivable from related party

$0

$36,234

'

'

'

'

'

'

$0

'

'

'

Common stock purchase warrant

'

'

'

'

'

'

'

'

'

'

1,000,000

3,000,000

Term of the warrants in years

'

'

'

'

'

'

'

'

'

'

'5 years

'5 years

Exercise price of a five-year warrant

'

'

'

'

'

'

'

'

'

'

$1.20

$1

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	1 Months Ended
	Apr. 30, 2013	Sep. 30, 2013
Loss Contingencies [Line Items]	'	'
Leasehold improvements	'	$1,800,000
Initial lease term	'10 years	'
Security deposit	64,000	'
Minimum [Member]	'	'
Loss Contingencies [Line Items]	'	'
Monthly payments under the lease	0	'
Maximum [Member]	'	'
Loss Contingencies [Line Items]	'	'
Monthly payments under the lease	$82,945	'

Roche_Collaboration_Option_and1

Roche Collaboration, Option and License Agreement (Details) (Collaborative Arrangement, Product [Member], USD $)	1 Months Ended
	Sep. 30, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'
Upfront payment received	$10,000,000
INO 5150 [Member]	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'
Revenue recognized	5,000,000
INO 1800 [Member]	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'
Revenue recognized	3,400,000
Option Right [Member] | License Arrangement [Member]	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'
Deferred revenue	1,500,000
Roche [Member]	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'
Upfront payment received	10,000,000
Development and regulatory event based payment receivable	412,500,000
Commercial event based payment received	0
Roche [Member] | INO 5150 [Member]	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'
Development and regulatory event based payment receivable	5,000,000
Roche [Member] | INO 1800 [Member]	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'
Development and regulatory event based payment receivable	$3,000,000

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	9 Months Ended		0 Months Ended		0 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Oct. 02, 2013	Dec. 31, 2012	Oct. 02, 2013
			Subsequent Event [Member]	Share Distribution [Member]	Share Distribution [Member]
					Subsequent Event [Member]
Subsequent Event [Line Items]	'	'	'	'	'
Upfront payment received	'	'	$10,000,000	'	'
Common stock sold under sales agreement	14,011,526	'	'	9,344,611	348,995
Proceeds from issuance of common stock and warrants	29,077,495	1,225,588	'	'	782,000
Common Sock Issued, Shares, Warrants	'	'	'	'	375,000
Proceeds from Warrant Exercises	'	'	$298,000	'	'